363 related articles for article (PubMed ID: 36720083)
21. The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer.
Melosky B; Cheema P; Juergens RA; Leighl NB; Liu G; Wheatley-Price P; Sacher A; Snow S; Tsao MS; McLeod D; Chu Q
Ther Adv Med Oncol; 2021; 13():17588359211056306. PubMed ID: 34804219
[TBL] [Abstract][Full Text] [Related]
22. TARGET: A Phase II, Open-Label, Single-Arm Study of 5-Year Adjuvant Osimertinib in Completely Resected EGFR-Mutated Stage II to IIIB NSCLC Post Complete Surgical Resection.
Soo RA; de Marinis F; Han JY; Ho JC; Martin E; Servidio L; Sandelin M; Popat S
Clin Lung Cancer; 2024 Jan; 25(1):80-84. PubMed ID: 37914594
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials.
Zhao P; Zhen H; Zhao H; Zhao L; Cao B
BMC Cancer; 2022 Mar; 22(1):328. PubMed ID: 35346117
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
Felip E; Altorki N; Zhou C; Csőszi T; Vynnychenko I; Goloborodko O; Luft A; Akopov A; Martinez-Marti A; Kenmotsu H; Chen YM; Chella A; Sugawara S; Voong D; Wu F; Yi J; Deng Y; McCleland M; Bennett E; Gitlitz B; Wakelee H;
Lancet; 2021 Oct; 398(10308):1344-1357. PubMed ID: 34555333
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant Treatments for Surgically Resected Non-Small Cell Lung Cancer Harboring EGFR Mutations: A Review.
Passaro A; Mok TSK; Attili I; Wu YL; Tsuboi M; de Marinis F; Peters S
JAMA Oncol; 2023 Aug; 9(8):1124-1131. PubMed ID: 37166792
[TBL] [Abstract][Full Text] [Related]
26. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.
Goss GD; O'Callaghan C; Lorimer I; Tsao MS; Masters GA; Jett J; Edelman MJ; Lilenbaum R; Choy H; Khuri F; Pisters K; Gandara D; Kernstine K; Butts C; Noble J; Hensing TA; Rowland K; Schiller J; Ding K; Shepherd FA
J Clin Oncol; 2013 Sep; 31(27):3320-6. PubMed ID: 23980091
[TBL] [Abstract][Full Text] [Related]
27. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS;
N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359
[TBL] [Abstract][Full Text] [Related]
28. A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer.
Wu YL; Tsuboi M; John T; Grohe C; Majem M; Goldman JW; Laktionov K; Kim SW; Kato T; Vu HV; Lu S; Lee KY; Akewanlop C; Yu CJ; de Marinis F; Bonanno L; Domine M; Shepherd FA; Zeng L; Hodge R; Atasoy A; Rukazenkov Y; Herbst RS
Future Oncol; 2021 Dec; 17(35):4827-4835. PubMed ID: 34723634
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2-IA3 EGFR-Mutated NSCLC: ADAURA2.
Tsutani Y; Goldman JW; Dacic S; Yatabe Y; Majem M; Huang X; Chen A; van der Gronde T; He J
Clin Lung Cancer; 2023 Jun; 24(4):376-380. PubMed ID: 36872181
[TBL] [Abstract][Full Text] [Related]
30. The Role of Adjuvant Chemotherapy before Osimertinib in Epidermal Growth Factor Receptor Mutant Resected Non-Small Cell Lung Cancer and Communicating It to Patients.
Maione P; Salvi R; Gridelli C
Curr Oncol; 2024 Feb; 31(2):987-997. PubMed ID: 38392068
[TBL] [Abstract][Full Text] [Related]
31. Epidermal growth factor receptor inhibitors as adjuvant treatment for patients with resected non-small cell lung cancer harboring EGFR mutation: a meta-analysis of randomized controlled clinical trials.
Zhao N; Wu ZP; Yang J; Feng WN; Yang SL; Luo Y; Ye J; Wang F; Zhang XW; Xiao Y; Wu LL; Gu WQ
World J Surg Oncol; 2023 Feb; 21(1):45. PubMed ID: 36782320
[TBL] [Abstract][Full Text] [Related]
32. Effective retreatment with osimertinib in CNS-relapsed epidermal growth factor receptor-mutant non-small cell lung cancer patient following resection and adjuvant osimertinib.
Di Federico A; De Giglio A; Sperandi F; Melotti B; Ardizzoni A; Gelsomino F
Anticancer Drugs; 2024 Jan; 35(1):86-88. PubMed ID: 37227039
[TBL] [Abstract][Full Text] [Related]
33. Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial.
Felip E; Altorki N; Zhou C; Vallières E; Martínez-Martí A; Rittmeyer A; Chella A; Reck M; Goloborodko O; Huang M; Belleli R; McNally V; Srivastava MK; Bennett E; Gitlitz BJ; Wakelee HA
Ann Oncol; 2023 Oct; 34(10):907-919. PubMed ID: 37467930
[TBL] [Abstract][Full Text] [Related]
34. Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer.
Lemmon CA; Zabor EC; Pennell NA
Oncologist; 2022 May; 27(5):407-413. PubMed ID: 35285487
[TBL] [Abstract][Full Text] [Related]
35. Gefitinib Versus Adjuvant Chemotherapy in Patients With Stage II-IIIA Non-Small-Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center Retrospective Study.
Xie H; Wang H; Xu L; Li M; Peng Y; Cai X; Feng Z; Ren W; Peng Z
Clin Lung Cancer; 2018 Nov; 19(6):484-492. PubMed ID: 30369426
[TBL] [Abstract][Full Text] [Related]
36. Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial.
Lu S; Wu L; Jian H; Cheng Y; Wang Q; Fang J; Wang Z; Hu Y; Han L; Sun M; Miao L; Ding C; Cui J; Wang K; Li B; Li X; Ye F; Liu A; Pan Y; Cang S; Zhou H; Sun X; Shen Y; Wang S; Zhang W; He Y
Lancet Respir Med; 2023 Jul; 11(7):624-636. PubMed ID: 37156249
[TBL] [Abstract][Full Text] [Related]
37. Alectinib in Resected
Wu YL; Dziadziuszko R; Ahn JS; Barlesi F; Nishio M; Lee DH; Lee JS; Zhong W; Horinouchi H; Mao W; Hochmair M; de Marinis F; Migliorino MR; Bondarenko I; Lu S; Wang Q; Ochi Lohmann T; Xu T; Cardona A; Ruf T; Noe J; Solomon BJ;
N Engl J Med; 2024 Apr; 390(14):1265-1276. PubMed ID: 38598794
[TBL] [Abstract][Full Text] [Related]
38. A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancer.
Cheng H; Li XJ; Wang XJ; Chen ZW; Wang RQ; Zhong HC; Wu TC; Cao QD
Lung Cancer; 2019 Nov; 137():7-13. PubMed ID: 31520922
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
Vansteenkiste JF; Cho BC; Vanakesa T; De Pas T; Zielinski M; Kim MS; Jassem J; Yoshimura M; Dahabreh J; Nakayama H; Havel L; Kondo H; Mitsudomi T; Zarogoulidis K; Gladkov OA; Udud K; Tada H; Hoffman H; Bugge A; Taylor P; Gonzalez EE; Liao ML; He J; Pujol JL; Louahed J; Debois M; Brichard V; Debruyne C; Therasse P; Altorki N
Lancet Oncol; 2016 Jun; 17(6):822-835. PubMed ID: 27132212
[TBL] [Abstract][Full Text] [Related]
40. Overall Survival with Osimertinib in Untreated,
Ramalingam SS; Vansteenkiste J; Planchard D; Cho BC; Gray JE; Ohe Y; Zhou C; Reungwetwattana T; Cheng Y; Chewaskulyong B; Shah R; Cobo M; Lee KH; Cheema P; Tiseo M; John T; Lin MC; Imamura F; Kurata T; Todd A; Hodge R; Saggese M; Rukazenkov Y; Soria JC;
N Engl J Med; 2020 Jan; 382(1):41-50. PubMed ID: 31751012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
